T
Tilman B. Drüeke
Researcher at Versailles Saint-Quentin-en-Yvelines University
Publications - 61
Citations - 3698
Tilman B. Drüeke is an academic researcher from Versailles Saint-Quentin-en-Yvelines University. The author has contributed to research in topics: Kidney disease & Cinacalcet. The author has an hindex of 22, co-authored 61 publications receiving 3114 citations. Previous affiliations of Tilman B. Drüeke include University of Picardie Jules Verne & University of Paris-Sud.
Papers
More filters
Journal ArticleDOI
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis
Evolve Trial Investigators,Glenn M. Chertow,Geoffrey A. Block,Ricardo Correa-Rotter,Tilman B. Drüeke,J. Floege,William G. Goodman,Charles A. Herzog,Yumi Kubo,Gérard M. London,Kenneth W. Mahaffey,Mix Tc,Sharon M. Moe,Marie-Louise Trotman,David C. Wheeler,Patrick S. Parfrey +15 more
TL;DR: In an unadjusted intention-to-treat analysis, cinacalcet did not significantly reduce the risk of death or major cardiovascular events in patients with moderate- to-severe secondary hyperparathyroidism who were undergoing dialysis.
Journal ArticleDOI
Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease
John J.V. McMurray,Patrick S. Parfrey,John W. Adamson,Pedro Aljama,Jeffrey S. Berns,Julia Bohlius,Tilman B. Drüeke,Fredric O. Finkelstein,Steven Fishbane,Tomas Ganz,Iain C. Macdougall,Ruth A. McDonald,Lawrence P. McMahon,Gregorio T. Obrador,Giovanni F.M. Strippoli,Günnter Weiss,Andrzej Wi¿cek +16 more
TL;DR: The 2012 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for Anemia in Chronic Kidney disease aims to provide guidance on diagnosis, evaluation, management and treatment for all CKD patients at risk of or with anemia.
Journal ArticleDOI
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis : The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
Sharon M. Moe,Glenn M. Chertow,Patrick S. Parfrey,Yumi Kubo,Geoffrey A. Block,Ricardo Correa-Rotter,Tilman B. Drüeke,Charles A. Herzog,Gérard M. London,Kenneth W. Mahaffey,David C. Wheeler,Maria Stolina,Bastian Dehmel,William G. Goodman,Jürgen Floege +14 more
TL;DR: In this paper, the effects of calcimimetic cinacalcet (versus placebo) on reducing serum fibroblast growth factor-23 and whether changes in FGF23 are associated with death and cardiovascular events.
Journal ArticleDOI
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Geoffrey A. Block,David A. Bushinsky,Sunfa Cheng,John Cunningham,Bastian Dehmel,Tilman B. Drüeke,Markus Ketteler,Reshma Kewalramani,Kevin J. Martin,Sharon M. Moe,Uptal D. Patel,Justin Silver,Yan Sun,Hao Wang,Glenn M. Chertow +14 more
TL;DR: Among patients receiving hemodialysis with moderate to severe secondary hyperparathyroidism, the use of etelcalcetide was not inferior to cinacalcet in reducing serum PTH concentrations over 26 weeks; it also met superiority criteria.
Journal ArticleDOI
Atherosclerosis in CKD: differences from the general population
Tilman B. Drüeke,Ziad A. Massy +1 more
TL;DR: It is hypothesized that the initial cardiovascular abnormalities in the CKD setting include arteriosclerosis, left ventricular diastolic dysfunction, andleft ventricular hypertrophy, abnormalities which, in adult patients, are often accompanied by atherosclerosis.